MXCT at a glance
MAXCYTE, INC. (MXCT, SEC CIK 1287098) filed its latest 10-K annual report on March 25, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), MAXCYTE, INC. (MXCT) reported revenue of $21.0 million (down 5.7% from FY2024) and a net loss of $44.6 million. Diluted EPS was -$0.42.
- As of September 30, 2026, 19 institutional investment managers tracked by SignalX reported holding MAXCYTE, INC. (MXCT) shares worth $22.7 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Masoud Maher on November 17, 2026 of 100,000 shares at $1.21 per share.
- In the last 90 days, MXCT insiders reported 1 open-market purchase ($121K) and 0 open-market sales ($0) on Form 4, a net purchase of $121K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $21.0M
- −5.7% vs prior year
- Insiders · 90 days
- 1 buy · 0 sells
- Net +$121K
- 13F holders
- 19 funds
- $22.7M · −1 vs prior quarter
- Latest 8-K
- Nov 10, 2026
- Item 2.02 · Item 1.01 · Item 3.02 · Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly added risk: proposed Akron acquisition may fail or be delayed, triggering unrecoverable transaction costs and potential stock-price decline
- Acquisition consideration: $105.0 million cash, 20,639,733 shares, and $20.0 million guaranteed deferred payments due January 2028 and January 2029
- Regulatory and compliance risk: Akron integration requires cGMP compliance and public-company financial controls
- Operational risk: limited experience with Akron’s reagent business may hinder integration, customer retention, and cross-selling
- Financial risk: proposed debt includes $20.0 million term borrowing and $2.0 million revolver borrowing at closing, with variable SOFR-based interest
Management Discussion & Analysis
- Revenue $10.2M, up 49% YoY from $6.8M, driven by SPL milestones and royalties
- Gross margin 83% vs 77% YoY, supported by higher-margin milestone and royalty revenue
- Best line: instrument revenue $2.8M, up 102%; weakest: Assay Service revenue down 83%
- Operating cash outflow $18.3M for nine months, versus $31.7M YoY; $5.5M stock repurchases
- Outlook: near-term operating losses, revenue volatility, and proposed Akron acquisition requiring $105.0M cash plus $22.0M initial debt draw
AI summary of the MXCT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 results for quarter ended September 30, 2026 announced November 10, 2026
- Press release contains the financial results and accompanying investor-relevant disclosures
Item 1.01: Entry into a Material Definitive Agreement
- MaxCyte acquiring Akron BioProducts for $105.0M cash, 20,639,733 shares, and $20.0M deferred cash
- Deferred payments split into $10.0M due in 2028 and $10.0M due in 2029, adding future cash obligations
Item 3.02: Unregistered Sales of Equity Securities
- 20,639,733 MXCT shares to be issued to sellers as stock consideration at transaction closing
- Private placement under Securities Act Section 4(a)(2), avoiding public registration
Item 7.01: Regulation FD Disclosure
- Acquisition announcement, investor presentation, and corporate presentation released November 10, 2026
- Closing depends on Hart-Scott-Rodino waiting-period expiration or termination
Item EX-99.2: Item EX-99.2
- Acquisition of Akron Bio for $151.8M, expected to close before year-end 2026
- Akron projected 2026 revenue $28M and EBITDA $7M-$8M, adding recurring consumables revenue
Item EX-99.4: Item EX-99.4
- Corporate presentation highlights 3Q26 core revenue $8.157M, up 27% year over year
- YTD 2026 total revenue $27.074M, up 5%, while core revenue declined 9% to $20.877M
Item EX-99.3: Item EX-99.3
- Acquisition consideration ~$151.8M: $105.0M cash, 20.6M shares, and $20.0M deferred payments in 2028–2029
- Akron adds $28M expected 2026 revenue, $7M–$8M EBITDA, and positive cash flow to roughly double MaxCyte’s revenue base
Item EX-99.1: Item EX-99.1
- Q3 revenue $10.2M, up 49%, with core revenue $8.2M up 27% and SPL revenue $2.0M
- Gross margin improved to 83% from 77%, while operating expenses fell to $14.5M from $19.4M
Item 2.02: Results of Operations and Financial Condition
- Preliminary unaudited revenue results for quarter ended September 30, 2026
- Full-year 2026 revenue guidance increased, signaling stronger expected business performance
Item EX-99.1: Item EX-99.1
- Preliminary Q3 core revenue $8.1M, up 26% year over year, signaling resumed growth
- SPL program revenue exceeded $1.0M, including a $1.0M milestone payment
Item EX-99.1#2: Item EX-99.1#2
- Corporate presentation updates investors on MaxCyte’s platform, customer pipeline, financial profile, and growth strategy as of August 2026
- Core revenue $12.7M, down 23% year-to-date, signaling continued weakness despite SPL-related revenue growth of 71% to $4.2M
Item 7.01: Regulation FD Disclosure
- Updated corporate presentation posted August 12, 2026 for investor communications and conferences
- Exhibit 99.2 contains management’s latest corporate messaging and strategy context
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026 announced August 12, 2026
- Full financial results and management commentary furnished in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue $7.3M, down 15% YoY; core revenue $6.5M, down 21%, signaling continued operating softness
- SPL revenue rose to $0.8M from $0.3M, driven by royalties up 150% to $0.8M
AI summaries of MXCT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for MXCT
Don't miss the next MXCT filing
- Alerts as it files. A push when MXCT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MXCT, by share count.
- Ask anything. An AI agent that reads every MXCT filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Masoud Maher | Buy | Nov 17, 2026 | 100,000 | $1.21 |
| Collins Cynthia | A | Jun 17, 2026 | 30,421 | - |
| Hemrajani Rekha | A | Jun 17, 2026 | 49,579 | - |
| Al-Wakeel Yasir B. | A | Jun 17, 2026 | 30,421 | - |
| Al-Wakeel Yasir B. | A | Jun 17, 2026 | 49,579 | - |
| Hemrajani Rekha | A | Jun 17, 2026 | 30,421 | - |
| DOUGLAS RICHARD | A | Jun 17, 2026 | 30,421 | - |
| Brooke William W | A | Jun 17, 2026 | 30,421 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $22.2M | $21.0M |
| Gross Profit | - | $31.5M | $26.8M |
| Operating Income | - | -$51.2M | -$51.9M |
| Net Income | - | -$41.1M | -$44.6M |
| Gross Margin | - | 141.9% | 127.9% |
| Op. Margin | - | -230.5% | -247.6% |
| Net Margin | - | -184.8% | -213.0% |
| Balance Sheet | |||
| Total Assets | $268.3M | $239.5M | $202.5M |
| Equity | - | $206.3M | $171.5M |
| ROE | - | -19.9% | -26.0% |
| Per Share | |||
| EPS | - | $-0.39 | $-0.42 |
| Cash Flow | |||
| Operating CF | - | -$27.6M | -$34.4M |
| CapEx | $3.7M | $1.7M | $1.8M |
Source: XBRL data in MAXCYTE, INC. (MXCT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate MXCT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 19 | $22.7M |
| Q2 2026 | 20 | $26.0M |
| Q1 2026 | 25 | $19.4M |
| Q4 2025 | 23 | $45.3M |
| Q3 2025 | 23 | $48.3M |
| Q2 2025 | 24 | $71.8M |
| Q1 2025 | 21 | $63.5M |
| Q4 2024 | 19 | $72.2M |
- Two Sigma Investments+946.9K (+65%)
- Citadel Advisors LLC+288.9K (+34%)
- Morgan Stanley+287.1K (+8%)
- Renaissance Technologies LLC+124.5K (+7%)
- Bank of America Corp+80.5K (+80%)
- AQR Capital Management−1.43M (-76%)
- Millennium Management−515.1K (-43%)
- Goldman Sachs Group−327.5K (-26%)
- BNY Mellon−47.9K (-60%)
- BlackRock−34.5K (-1%)
- FMR LLC (Fidelity)−180.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 174 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
MXCT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 18, 2026 | - | - | - |
| 8-K | Nov 10, 2026 | - | Analysis | - |
| 10-Q | Nov 10, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 14, 2026 | - | Analysis | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| SC 13D | Aug 4, 2026 | - | - | |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 8-K | Jun 17, 2026 | - | Analysis | - |
| 8-K | Jun 16, 2026 | - | Analysis | - |
| SC 13D | May 14, 2026 | - | - | |
| 10-Q | May 13, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 12, 2026 | - | Analysis | |
| 4 | Apr 17, 2026 | - | - | - |
| 4 | Apr 10, 2026 | - | - | - |
| 4 | Mar 31, 2026 | - | - | - |
| 8-K | Mar 27, 2026 | - | - | - |
| 10-K | Mar 25, 2026 | Dec 31, 2025 | - |
Related Health Care companies
- ABSI · Absci CorpServices-Commercial Physical & Biological Research
- CRL · Charles River LaboratoriesServices-Commercial Physical & Biological Research
- INCY · IncyteServices-Commercial Physical & Biological Research
- IQV · IQVIAServices-Commercial Physical & Biological Research
- MEDP · Medpace Holdings IncServices-Commercial Physical & Biological Research
- NRC · NATIONAL RESEARCH CORPServices-Commercial Physical & Biological Research
- OABI · OmniAb, Inc.Services-Commercial Physical & Biological Research
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
MXCT SEC filings: frequently asked questions
Are MXCT insiders buying or selling?
In the last 90 days, MAXCYTE, INC. (MXCT) officers, directors and 10% owners reported 1 open-market purchase worth $120,780 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold MXCT stock?
As of September 30, 2026, the largest MAXCYTE, INC. (MXCT) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($4.5 million), Morgan Stanley ($4.5 million), BlackRock ($3.4 million), Two Sigma Investments ($2.7 million), Renaissance Technologies LLC ($2.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was MXCT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), MAXCYTE, INC. (MXCT) reported revenue of $21.0 million (down 5.7% from FY2024) and a net loss of $44.6 million. Diluted EPS was -$0.42. The figures come from the XBRL data in the 10-K.
What did MXCT report in its latest 8-K?
MAXCYTE, INC. (MXCT) filed an 8-K on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities) and Item 7.01 (Regulation FD Disclosure). Q3 2026 results for quarter ended September 30, 2026 announced November 10, 2026.
What are the latest MXCT SEC filings?
MAXCYTE, INC. (MXCT) filed its latest 10-K annual report on March 25, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on November 18, 2026.
What is MXCT's SEC CIK number?
MAXCYTE, INC. (MXCT)'s SEC Central Index Key (CIK) is 1287098. EDGAR lists every MXCT filing under that number.
Ask anything about MXCT
The research agent reads MXCT's filings, financials, insider trades and 13F holders, then answers with sources.